Abstract

We attempts to discuss the clinical efficacy and application of calcium dobesilate combined with ranibizumab in patients with macular edema secondary to branch retinal vein occlusion. We randomly selected 100 patients with macular edema secondary to branch retinal vein occlusion who had accepted therapy in our hospital from September 2019 to September 2021 as general data. Then divided them into two groups, one was observation group and the other was control group (n=50). Among them, control group was treated with ranibizumab and observation group was treated with calcium dobesilate combined with ranibizumab. Observation group had better changes of best corrected visual acuity and macular foveal thickness after 1 mo, 3 mo and 6 mo treatment than control group. Observation group had better clinical efficacy than control group. Control group had more serious complications than observation group. Calcium dobesilate combined with ranibizumab has a significant clinical effect on patients with macular edema secondary to branch retinal vein occlusion and can reduce complications in patients.